Literature DB >> 13680215

Characterization of coxsackievirus B3-caused apoptosis under in vitro conditions.

Ulrike Martin1, Matthias Nestler, Thomas Munder, Roland Zell, Holger H Sigusch, Andreas Henke.   

Abstract

Among several mechanisms of pathogenesis of the frequent and sometimes serious infections with coxsackievirus B3 (CVB3), one detail is apoptosis. Recently, a new apoptotic mechanism involving the specific interaction between the capsid protein VP2 of the highly virulent variant CVB3H3 and the proapoptotic host protein Siva was identified. The relevance of this observation for virus pathogenicity was shown in a BALB/c mouse model using CVB3H3 and the interaction-deficient mutant virus CVB3H310A1. In this study these results were verified and extended under in vitro conditions. The different apoptotic capability of CVB3H3 versus CVB3H310A1 was demonstrated by apoptotic nuclear condensation, DNA fragmentation, expression of Siva mRNA, and caspase-3 activation. The virus-specific differences were caused by the VP2 capsid proteins, which was shown by overexpression of the single VP2H3 and VP2H310A1 protein. Furthermore, the involvement of apoptosis in virus progeny production and the associated appearance of the cytopathic effect was demonstrated by application of the pan-caspase inhibitor Z-VAD-FMK. These in vitro results indicate that the induction of apoptosis during CVB3H3 infection is based on the interaction between the capsid protein VP2 and the proapoptotic protein Siva, independently from the complex situation in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680215     DOI: 10.1007/s00430-003-0197-7

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  14 in total

Review 1.  Molecular aspects of myocarditis.

Authors:  N E Bowles; J A Towbin
Journal:  Curr Opin Cardiol       Date:  1998-05       Impact factor: 2.161

Review 2.  Enteroviruses in human disease.

Authors:  N R Grist; E J Bell; F Assaad
Journal:  Prog Med Virol       Date:  1978

Review 3.  The group B coxsackieviruses and myocarditis.

Authors:  K S Kim; G Hufnagel; N M Chapman; S Tracy
Journal:  Rev Med Virol       Date:  2001 Nov-Dec       Impact factor: 6.989

4.  Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice.

Authors:  S A Huber
Journal:  Lab Invest       Date:  1997-05       Impact factor: 5.662

5.  Apoptosis in the failing human heart.

Authors:  G Olivetti; R Abbi; F Quaini; J Kajstura; W Cheng; J A Nitahara; E Quaini; C Di Loreto; C A Beltrami; S Krajewski; J C Reed; P Anversa
Journal:  N Engl J Med       Date:  1997-04-17       Impact factor: 91.245

6.  Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva.

Authors:  A Henke; H Launhardt; K Klement; A Stelzner; R Zell; T Munder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.

Authors:  J R Gebhard; C M Perry; S Harkins; T Lane; I Mena; V C Asensio; I L Campbell; J L Whitton
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

9.  Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells.

Authors:  C M Carthy; D J Granville; K A Watson; D R Anderson; J E Wilson; D Yang; D W Hunt; B M McManus
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  Differential effects of myocarditic variants of Coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage.

Authors:  L H Chow; C J Gauntt; B M McManus
Journal:  Lab Invest       Date:  1991-01       Impact factor: 5.662

View more
  5 in total

1.  Stress-activated protein kinases are involved in coxsackievirus B3 viral progeny release.

Authors:  Xiaoning Si; Honglin Luo; Andrew Morgan; Jingchun Zhang; Jerry Wong; Ji Yuan; Mitra Esfandiarei; Guang Gao; Caroline Cheung; Bruce M McManus
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  The anti-obesity drug orlistat reveals anti-viral activity.

Authors:  Elisabeth Ammer; Sandor Nietzsche; Christian Rien; Alexander Kühnl; Theresa Mader; Regine Heller; Andreas Sauerbrei; Andreas Henke
Journal:  Med Microbiol Immunol       Date:  2015-02-14       Impact factor: 3.402

3.  Characterization of coxsackievirus B3 replication in human umbilical vein endothelial cells.

Authors:  A Kühnl; C Rien; K Spengler; N Kryeziu; A Sauerbrei; R Heller; A Henke
Journal:  Med Microbiol Immunol       Date:  2014-03-11       Impact factor: 3.402

4.  Coxsackievirus B3-induced cellular protrusions: structural characteristics and functional competence.

Authors:  Outi Paloheimo; Teemu O Ihalainen; Sisko Tauriainen; Outi Välilehto; Sanna Kirjavainen; Einari A Niskanen; Johanna P Laakkonen; Heikki Hyöty; Maija Vihinen-Ranta
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

5.  Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.

Authors:  Sabine M G van der Sanden; Weilin Wu; Naomi Dybdahl-Sissoko; William C Weldon; Paula Brooks; Jason O'Donnell; Les P Jones; Cedric Brown; S Mark Tompkins; M Steven Oberste; Jon Karpilow; Ralph A Tripp
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.